About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials | 6,613 Studies Recruiting

Clinical TrialsLymphoma

Lymphoma Clinical Trials

Browse 6,613 clinical trials for lymphoma. Find studies that match your criteria and connect with research centers.

Find trials near:

New York Los Angeles Chicago Houston Phoenix Philadelphia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 121-140 of 6,613 trials

Active not recruitingStudy of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5This study is a phase III, randomized, open-label, international, multicenter, interventional trial, designed to compare the efficacy and safety of mosunetuzumab in combination…NCT06284122·Graz and 110 others

Related Searches

hodgkintrials non-hodgkintrials

Data from ClinicalTrials.govTerms

UnknownAllogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell LymphomaPreclinical and clinical studies of CD19 CAR-T in r/r B-NHL have been extensively carried out.NCT05143112·Shenzhen, Guangdong

CompletedThe Clinical Implications of Immune Checkpoint Pathways in PCNSLCentral nervous system lymphoma (CNSL) is a rare brain tumor constituting 3% of all newly diagnosed brain tumors, and 2% to 3% of all cases of non-Hodgkin lymphoma.NCT04158128·Taipei

UnknownEfficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell LymphomaThe most common option of radiotherapy for patients with limited-stage DLBCL is involved-field radiotherapy (IFRT).NCT02449265·Wuhan, Hubei

TerminatedFR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaFR901228 may stop the growth of cancer cells by blocking some of the enzymes needed for cell to grow and by blocking blood flow to the cancer.NCT00383565·Houston, Texas

UnknownSafety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell LymphomaThis is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of CD19-PD1-CART cells therapy for patients with relapsed/refractory B Cell…NCT04163302·Sanya, Hainan

TerminatedRituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's LymphomaMonoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.NCT00301795·Chicago, Illinois

UnknownAnti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma.Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies.NCT04639739·Chongqing, Chongqing Municipality

CompletedMulti-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating FactorThis international, prospective, observational, open-label, pharmaco-epidemiologic study observes cancer patients at risk for chemotherapy-induced febrile neutropenia (FN) who are…NCT01459653·Innsbruck and 116 others

CompletedStudy to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)The primary objective of this study is to evaluate the 28-day safety and tolerability, and to determine the pharmacokinetics (PK) of idelalisib in Japanese participants with…NCT02242045·Aichi and 2 others

CompletedKX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to TreatmentRATIONALE: KX2-391 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.NCT00646139·Buffalo, New York

CompletedLithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantRATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant.NCT00408681·Seattle, Washington

UnknownPrognostic Nomogram of Extranodal NK/T-cell LymphomaThis study aims to evaluate prognostic factors for overall survival and explore risk progression-free survival in ENKTL, and establish a prognostic predictive nomogram for ENKTL…NCT04554511·Guangzhou, Guangdong

CompletedImmunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular LymphomaFollicular lymphoma has historically been considered an incurable lymphoma.NCT01130194·St Louis, Missouri

CompletedMonoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular LymphomaThe goal of this clinical research study is to learn if the combination of the immunotherapy drugs, CT-011 and rituximab, can help control follicular lymphoma.NCT00904722·Houston, Texas

RecruitingPhase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCLThis is a phase 2, open-label, randomized, multicenter clinical trial in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who meet the criteria for…NCT06553872·Stanford, California and 2 others

Enrolling by invitationStudy on Treatment Mechanisms and Efficacy Prediction of Individualized Transcranial Magnetic Stimulation in Adults With Irritable Bowel Syndrome Using Multimodal MRI and High-Throughput SequencingThe goal of this clinical trial is to explore if "individualized repetitive Transcranial Magnetic Stimulation (TMS)" works to improve symptoms in adults with Irritable Bowel…NCT07345377·Hangzhou, Zhejiang

WithdrawnStudy of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHLThe goal of this study is to evaluate a new approach to immunotherapy in NHL by combining two antibodies, veltuzumab and epratuzumab.NCT01101581·Newark, Delaware and 6 others

CompletedEvaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's LymphomaThis is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetic (PK) of GDC-0349 administered once daily (QD), orally…NCT01356173·Scottsdale, Arizona and 1 other

Not yet recruitingMRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell LymphomaThis prospective feasibility study evaluates a minimal residual disease (MRD)-adapted treatment strategy in patients with diffuse large B-cell lymphoma (DLBCL) receiving frontline…NCT07517705·Omaha, Nebraska

PreviousPage 7 of 331Next